Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

27 March 2025

Aspen Biopharma Labs gets warning letter from USFDA

The U.S. Food and Drug Administration inspected Aspen Biopharma Labs Private Limited, drug facility; at Rangareddy region from September 16 to September 21, 2024. And they get a warning letter which summarizes significant deviations from Current Good Manufacturing Practice CGMP for active pharmaceutical ingredients.
26 March 2025

Growing Body of Evidence Links HPV with Heart Disease

In addition to causing several types of cancer, human papillomavirus appears to bring a significantly increased risk of heart disease and coronary artery disease, according to a study being presented at the American College of Cardiology's Annual Scientific Session.
26 March 2025

New Evidence Links Microplastics with Chronic Disease

Tiny fragments of plastic have become ubiquitous in our environment and our bodies. Higher exposure to these microplastics, which can be inadvertently consumed or inhaled, is associated with a heightened prevalence of chronic noncommunicable diseases, according to new research being presented at the American College of Cardiology's Annual Scientific Session (ACC.25).
26 March 2025

Blujepa (gepotidacin) approved by USFDA for treatment of uncomplicated urinary tract infections

Discovered by GSK scientists, Blujepa is a first-in-class oral antibiotic with a novel mechanism of action that is part of GSK’s infectious diseases portfolio.
24 March 2025

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

Innovent Biologics, Inc , a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed with IBI354
21 March 2025

Novartis receives third FDA approval for oral Fabhalta® (iptacopan)

Novartis announced that oral Fabhalta iptacopan has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition.
19 March 2025

AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets. Alteogen will be responsible for clinical and commercial supply of ALT-B4 to AstraZeneca.
19 March 2025

Zydus receives final approval from USFDA for Apalutamide Tablets, 60 mg

Zydus Life sciences Limited has received final approval from the United States Food and Drug Administration USFDA to manufacture Apalutamide Tablets, 60 mg.
19 March 2025

Sun Pharma completes acquisition of Antibe Therapeutics in CAD 4.5 million

TARO Pharmaceuticals Inc., a subsidiary of Sun Pharma, has completed 100 percent acquisition of Antibe Therapeutics Inc., Canada for a total consideration of CAD 4.5 million.
Antibe Therapeutics is an Ontario, Canada incorporated corporation based in Ontario, Canada. It is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation.
19 March 2025

Treating chronic inflammatory diseases with JAK inhibitors

Janus kinase inhibitors are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohns disease or ulcerative colitis. Since their approval, the indications for these medical drugs have steadily increased, but recently safety concerns have also been raised.